A multicenter phase l/ll study of obatoclax mesylate administered as a 3- Or 24-hour infusion in older patients with previously untreated acute myeloid leukemia

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Schimmer, Aaron D ^a   Raza, Azra ^b   Carter, Thomas H ^c   Claxton, David ^d   Erba, Harry ^e   DeAngelo, Daniel J ^f   Tallman, Martin S ^g   Goard, Carolyn ^a   Borthakur, Gautam ^h  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Department of Medicine   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OBATOCLAX; PYRROLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; ACUTE SINUSITIS; AGED; ARTICLE; ATAXIA; CATHETER INFECTION; CLINICAL ARTICLE; CONFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE SYNDROME; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MOOD DISORDER; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SPEECH DISORDER; VERY ELDERLY; BLAST CRISIS; BLOOD; CLINICAL TRIAL; DEMOGRAPHY; DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; NEUTROPHIL; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLAST CRISIS; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; NEUTROPHILS; PLATELET COUNT; PYRROLES; TREATMENT OUTCOME;

EID: 84907859379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108694     Document Type: Article

References (32)

1. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368: 1894 -1907.
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11 -30.
3. National Cancer Institute. SEER Stat Fact Sheets: Leukemia. Available: seer.cancer.gov/statfacts/html/leuks.html. Accessed: 2014 Apr 17.
4. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010) The BCL-2 family reunion. Mol Cell 37: 299-310.
5. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656.
6. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, et al. (2012) Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 26: 120-125.
7. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
8. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517.
9. Zhai D, Jin C, Satterthwait AC, Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13: 1419-1421.
10. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, et al. (2008) Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 68: 3413 -3420.
11. Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, et al. (2010) Phase I dose finding studies of obatoclax (G×15-070), a small molecule pan-BCE-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 16: 4038-4045.
12. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, et al. (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113: 299-305.
13. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, et al. (2012) Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119: 2171-2172.
14. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, et al. (2008) A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14: 8295-8301.
15. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, et al. (2010) Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 10: 285-289.
16. Raza A, Galili N, Borthakur G, Carter TH, Claxton DF, et al. (2009) A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol 27: suppl; abstr 3579.
17. National Cancer Instititute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available: Accessed: 2014 Apr 17.
18. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649.
19. Li H, Chen Y, Jones AF, Sanger RH, Collis LP, et al. (2008) Bcl-xL induces Drp 1 -dependent synapse formation in cultured hippocampal neurons. Proc Nad Acad Sci U S A 105: 2169-2174.
20. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, et al. (1998) Transgenic mice expressing human Bel-2 in their neurons are resistant to 6-hydroxydopamine and 1 -methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A 95: 5789-5794.
21. Park PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, et al. (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74: 481-4-85.
22. Dewson G, Kluck RM (2010) Bel-2 family-regulated apoptosis in health and disease. Cell Health Cytoskel 2: 9-22.
23. Thomas M, Gessner A, Vornlocher HP, Hadwiger P, Greil J, et al. (2005) Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 106: 3559-3566.
24. Izon DJ, Rozenfeld S, Fong ST, Komuves L, Largman C, et al. (1998) Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes. Blood 92: 383-393.
25. Rooswinkel RW, van de Kooij B, Verheij M, Borst J (2012) Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 3: e366.
26. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421 -3428.
27. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, et al. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30: 488-496.
28. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, et al. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11: 1149-1159.
29. Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, et al. (2011) BCL2/ BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 117: 7145-7154.
30. Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, et al. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 153: 599-611.
31. Campas C, Cosialls AM, Barragan M, Iglesias-Serret D, Santidrian AF, et al. (2006) Bel-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 34: 1663-1669.
32. Rahmani M, Aust MM, Attkisson E, Williams DC, Jr., Ferreira-Gonzalez A, et al. (2012) Inhibition of Bel-2 antiapoptotic members by obatoclax potentiy enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 119: 6089-6098.